You are here
SPIRIT: Higher MMR Rate With Imatinib/Peginterferon vs Imatinib Alone & Imatinib/Cytarabine in Patients with Newly Diagnosed CML
SPIRIT: Higher MMR Rate With Imatinib/Peginterferon vs Imatinib Alone and Imatinib/Cytarabine in Patients with Newly Diagnosed CP-CML
Posting Date: December 09, 2008
Interim analysis of the STI571 Prospective Randomized Interferon Trial (SPIRIT) from the French Chronic Myeloid Leukemia (CML) Group: multicenter, open-label, prospective, randomized, phase III trial
Summary of Key Conclusions
Preliminary analysis of 4 imatinib-based regimens finds that significantly more patients with newly diagnosed chronic-phase CML attained major molecular response with imatinib/peginterferon alfa-2a combination therapy vs standard-dose imatinib after 12 months
Rates of imatinib discontinuation comparable across all 4 arms
Higher incidence of grade 3/4 toxicity observed with higher-dose imatinib and imatinib combination therapies vs standard-dose imatinib